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The development of a safe and effective adjuvant that amplifies the immune
response to an antigen is important for vaccine delivery. In this study, we
developed pristine mesoporous carbon hollow spheres as high-capacity vaccine 
protein nanocarriers and safe adjuvants for boosting the immune response. 
Mono-dispersed invaginated mesostructured hollow carbon spheres (IMHCSs)
have an average particle size of ~200 nm, large pore size of 15 nm, and high 
pore volume of 2.85 cm3·g–1. IMHCSs exhibited a very high loading capacity 
(1,040 μg·mg–1) towards ovalbumin (OVA, a model antigen), controlled OVA
release behavior, excellent safety profile to normal cells, and high antigen delivery
efficacy towards macrophages. In vivo immunization studies in mice demonstrated
that OVA-loaded IMHCSs induced a 3-fold higher IgG response compared to a 
traditional adjuvant QuilA used in veterinary vaccine research. OVA delivered by
IMHCSs induced a higher IgG1 concentration than IgG2a, indicating a T-helper 2
(Th2)-polarized response. Interferon-γ and interleukin-4 concentration analysis 
revealed both T-helper 1 (Th1) and Th2 immune responses induced by OVA-
loaded IMHCSs. IMHCSs are safer adjuvants than QuilA. Our study revealed that
pure IMHCSs without further functionalization can be used as a safe adjuvant 




Vaccines aim to induce effective long-term immune 
response towards specific antigens and provide 
protection against diseases [1]. Recombinant/subunit 
vaccines are safer alternatives for use in attenuated 
vaccines with reduced side effects compared to older- 
style live or killed whole organism vaccines [1, 2]. 
However, the immunogenicity imparted by these 
vaccines is relatively low, and thus exogenous adjuvants 
are used to enhance the immune response [3]. 
Incorporation of adjuvants in the vaccine formulation 
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also helps to achieve qualitative T-helper 1 (Th1) and 
T-helper 2 (Th2) responses [4]. Th1 cells induce cell- 
mediated responses by affecting cytokines such as 
interferon (IFN)-γ, whereas Th2 cells provide humoral 
and mucosal immunity through cytokines such as 
interleukin (IL)-4 [5]. Both Th1 and Th2 responses  
are required for efficient activation of an immune 
response [4].  
Since 1920, various adjuvants have been studied, 
including Alum, Freund’s adjuvant, QuilA, and 
lipopolysaccharides [6, 7]. Most of these adjuvants 
exhibit toxicity and cause local allergies [8–10]. In 
recent years, nanoparticles have attracted attention as 
nanocarriers and self-adjuvants [11, 12]. Encapsulation 
of antigen proteins in a nanocarrier can improve the 
delivery efficacy of antigens to antigen-presenting 
cells (APCs) [13], extend the antigen release profile, 
and enhance the levels of immune response [14]. 
Nanoparticles such as liposomes, chitosan, virus-like 
particles, layered double hydroxides, carbon, poly(lactic- 
co-glycolic acid) (PLGA), and mesoporous silica nano-
particles have been reported as effective adjuvants 
for improving the immune response of ovalbumin 
(OVA), a model antigen protein [15–20]. However, 
these particles lack high antigen loading [15, 21]. This 
limitation can be partially circumvented by surface 
hydrophobicity modification of nanoparticles, which 
improves antigen loading capacity and sustained 
release behavior, antigen uptake by macrophages, 
and eventually the immune response [13, 22, 23]. 
Nevertheless, the introduced hydrophobic groups 
lead to increased toxicity [24]. It remains a challenge 
to develop nanoparticle-based adjuvants with a large 
antigen loading capacity, high safety profile, and 
excellent adjuvant effects to stimulate an immune 
response. 
Carbon nanoparticles with intrinsic hydrophobicity 
have widespread bio-applications [25, 26]. Carbon 
nanotubes (CNTs) are the most commonly studied 
carbon materials with demonstrated adjuvant effects 
[27]. However, CNTs cannot load proteins inside the 
channel because of their small size, and thus vaccine 
proteins are generally attached to the outer surface of 
CNTs using coupling agents [25, 28] with limited 
antigen levels [27]. As the protein is not loaded inside 
the channel, it is still exposed to degrading enzymes, 
causing instability issues [27]. Recently, mesoporous 
carbon nanoparticles (MCNs) have attracted attention 
in cellular delivery [29, 30]. However, there are no 
reports of using MCNs as high-capacity antigen protein 
carriers and effective adjuvants for vaccine delivery. 
We previously reported the synthesis of mesostructured 
hollow carbon spheres (MHCSs) with invaginated 
and intact morphologies with a high protein loading 
capacity [31]. Invaginated MHCSs (IMHCSs) exhibited 
higher hemocompatibility compared to the intact 
structure [31]. The recent progress in the synthesis  
of MCNs encouraged us to explore the potential of 
IMHCSs as an adjuvant in vaccine delivery.  
In the present study, we evaluated the application 
of IMHCSs as an adjuvant for the delivery of an antigen 
protein OVA. IMHCSs showed high loading towards 
OVA (Fig. 1). OVA-loaded IMHCSs exhibited enhanced 
uptake in APCs, which induced the activation of 
co-stimulatory molecules (CD40, MHCII) expressed 
on the surface of maturized APCs. In vivo mouse 
studies showed that OVA-loaded IMHCSs induced a 
3-fold higher IgG response compared to a traditional 
adjuvant QuilA. 
Moreover, IMHCS-OVA induced a higher IgG1 
concentration than IgG2a and high IL-4 secretion, 
suggesting a Th2-polarized immune response. Our 
results demonstrate that pure IMHCSs can be used as 
a safe adjuvant for vaccine delivery. 
 
Figure 1 Schematic illustration of OVA-loaded IMHCSs with 
enhanced uptake in APCs and higher secretion of IL-4 compared 
to IFN-γ causing a Th2-biased response. 
2 Experimental 
2.1 Chemicals  
Tetraethylorthosilicate (TEOS), resorcinol, OVA, for-
malin (37 wt.%), CNT, 3-[4,5-dimethylthiazol-2-yl]- 
2,5-diphenyltetrazolium bromide (MTT), bovine serum 
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albumin (BSA), fluorescein isothiocyanate (FITC), OVA 
tagged with FITC (OVAF), ethylene diamine tetra acetic 
acid, and dimethyl sulfoxide were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Ammonia aqueous 
solution (28 wt.%) and hydrogen fluoride were from 
Merck Laboratories (Kenilworth, NJ, USA). Ethanol 
was received from RCI Labscan, Ltd. (Bangkok, 
Thailand). QuilA was supplied from Superfos Biosector 
(Vedback, Denmark). Penicillin, streptomycin, phosphate- 
buffered saline (PBS), and Dulbecco’s Modified Eagle’s 
medium (DMEM) were from Gibco Invitrogen 
Corporation/Life Technologies (Carlsbad, CA, USA). 
Fetal bovine serum (FBS) was obtained from Moregate 
Biotech (Bulimba, Australia). 
2.2 Synthesis of IMHCSs 
IMHCSs were synthesized as described previously 
[31]. In a typical synthesis, 2.8 mL TEOS, 0.4 g resorcinol, 
and 0.56 mL formalin (37 wt.%) were added to a 
solution containing 70 mL ethanol, 10 mL deionized 
water, and 3.0 mL ammonia aqueous solution (28 wt.%) 
while stirring at 25 °C. The reaction solution was stirred 
for 6 h, followed by a second addition of 1.5 mL of 
TEOS and additional stirring for 24 h. The solid product 
was collected by centrifugation at 48,380g for 15 min, 
washed twice with ethanol, and dried at 50 °C overnight. 
The dried product was carbonized at 700 °C under   
a N2 atmosphere for 5 h, followed by 5% hydrogen 
fluoride etching treatment to remove the silica. Finally, 
IMHCSs were obtained after washing twice with water 
and drying in air.  
2.3 Characterization 
The morphology of IMHCSs and CNTs was observed 
using a transmission electron microscope (TEM) (JEOL 
1010, Tokyo, Japan) operated at 100 kV. The samples 
were prepared by drying ethanol-sample dispersion 
on copper grids. Scanning electron microscopy (SEM) 
images were recorded on a field emission scanning 
electron microscope (FESEM, JEOL 7001) operated  
at 10 kV. Nitrogen adsorption–desorption isotherms 
were measured at 77 K by using a Micromeritics 
Tristar II system (Norcross, GA, USA). The samples 
were degassed at 180 °C overnight on a vacuum line. 
The Brunauer–Emmett–Teller (BET) method was 
utilized to calculate the specific surface area. Pore 
size distribution curves were derived from both the 
adsorption and desorption branches of the isotherms 
using the Barrett–Joyner–Halanda method. Total pore 
volume was calculated from the amount adsorbed at 
a maximum relative pressure (P/P0). Dynamic light 
scattering (DLS) measurements were carried out at 
37 °C on a Malvern Nano ZS Zetasizer instrument 
(Malvern, UK) using ethanol, PBS (pH 7.4), and DMEM 
supplemented with FBS (10%), L-glutamine (2%), 
penicillin (1%), and streptomycin (1%) as solvents. 
2.4 OVA adsorption on IMHCSs and CNTs  
OVA was adsorbed onto IMHCSs or CNTs by mixing 
2 mg of OVA with 1 mg IMHCS or CNT in 1 mL PBS 
(pH = 7.4). The mixtures were placed in a shaker at 
200 rpm for 24 h at 4 °C. The supernatant was collected 
by centrifugation at 15,000 rpm for 15 min and then 
analyzed using a Bicinchoninic Acid assay kit (BCA, 
Pierce, Rockford, IL, USA). The adsorption capacity 
of OVA was calculated based on the original and 
residual concentrations remaining in the supernatant. 
All experiments were performed in triplicate. OVA 
adsorption capacity was calculated using the following 
equation 
OVA adsorption capacity (mg·mg−1) = [C(original 
OVA, mg·mg−1) – C(residual OVA, mg·mg−1)] × volume 
of mixture (mL)/w (IMHCS/CNT, mg). 
2.5 OVA desorption from IMHCSs and CNTs 
OVA-adsorbed IMHCSs or CNTs were suspended in 
1 mL PBS buffer and placed in a shaker at 200 rpm 
and 37 °C. After specific time intervals, 400 μL super-
natant was collected by centrifugation at 15,000 rpm 
for 10 min and replaced by 400 μL fresh PBS. OVA 
concentration in the supernatant was estimated using 
the BCA assay kit. 
2.6 Cell culture 
Cell culture reagents were purchased from GIBCO 
Sciences (Grand Island, NY, USA) unless otherwise 
specified. Human embryonic kidney 293 (HEK 293, 
CRL 1573) and RAW 264.7 (mouse macrophages) cells 
were obtained from American Type Culture Collection 
(Manassas, VA, USA) and Cell Bank Australia 
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(Westmead, Australia), respectively. The cells were 
maintained in a 37 °C, 5 % CO2 incubator in complete 
DMEM. Sub-culturing was carried out every 2 days. 
2.7 Cell viability assay  
The cell viabilities of IMHCS-, CNT-, OVA plus 
QuilA-, and OVA-loaded IMHCSs were tested using 
HEK 293 cells. A total of 25,000 cells were seeded into 
each well of a 24-well plate. After 24 h of incubation, 
the culture medium was replaced with 1 mL OVA 
plus QuilA (50 + 25 μg·mg−1), OVA-loaded IMHCSs 
(equivalent to 50 μg·mg−1 of OVA), CNTs (12–     
100 μg·mg−1), and IMHCS nanoparticles (25–400 μg·mg−1) 
suspended in serum-free DMEM. After further 
incubation for 24 h, the medium was removed and  
1 mL fresh complete DMEM containing 10% FBS, 1% 
penicillin, and streptomycin was added to each well, 
followed by addition of 100 L MTT PBS solution   
(5 mg·mg−1). The plate was then placed in a 37 °C, 5% 
CO2 incubator for 4 h before adding 1 mL dimethyl 
sulfoxide to each well. Supernatant solutions were 
collected and centrifuged for 15 min at 15,000 rpm 
and the absorbance for the supernatants placed in a 
new plate were measured at a wavelength of 570 nm 
using a plate reader. Untreated incubated cells were 
used as a control. All experiments were performed in 
triplicate for each group [32]. 
2.8 Preparation of FITC-grafted IMHCSs and CNTs 
FITC was grafted onto IMHCSs and CNTs as described 
previously [33]. First, 25 mg IMHCS or CNT and 
0.15 mg FITC were ultrasonicated in 6.5 mL anhydrous 
tetrahydrofuran. The resultant solution was then 
stirred at 30 °C for 2 h. The mixture was centrifuged at 
15,000 rpm for 15 min. The IMHCS and CNT labeled 
with FITC were further washed with PBS solution 
several times. Absorbance of the supernatant and 
washing medium was measured by ultraviolet–visible 
(UV–Vis) spectroscopy, which showed negligible 
readings in both particle systems, suggesting that all 
FITC had attached to the nanoparticles. 
2.9 Cellular uptake of IMHCS-F and CNT-F 
Cellular uptake studies for IMHCSs and CNTs were 
carried out by tagging the nanoparticles with FITC 
and OVAF-loaded nanoparticles [33]. A total of 2.5  
105 RAW 264.7 cells per well were seeded into a 
12-well plate. After 48 h of incubation, 10 μg FITC- 
tagged nanoparticles was added to each well and 
incubated for 2 h in a 37 °C, 5% CO2 incubator. After 
removing the supernatant, the cells were washed 
twice with sterile PBS and collected. The harvested cells 
were washed twice with sterile PBS and then suspended 
in the FACS buffer (500 mg BSA, 50 mg EDTA, and 
100 mL PBS free from calcium and magnesium salts). 
FITC uptake in the cells was analyzed using FACS 
BD LSR II Analyzer (BD Biosciences, Franklin Lakes, 
NJ, USA). 
2.10 Confocal microscopy 
Cellular uptake was also studied by confocal micros-
copy on RAW 264.7 cells. A total of 1  106 cells was 
adhered onto a sterile microscopic coverslip at 37 °C 
for 24 h. After 24 h, the medium was replaced with 
serum-free medium and the cells were treated with 
FITC-tagged nanoparticles and OVAF-loaded nano-
particles (CNT-FITC, IMHCS-FITC). The cells were 
fixed with 4% formaldehyde and permeabilized with 
1% BSA for 30 min. Finally, the coverslips were placed 
on 4’,6-diamidino-2-phenylindole, dihydrochloride 
(DAPI) and viewed under a 40× confocal laser-scanning 
microscope (LSM510META, Zeiss, Jena, Germany). 
2.11 Intracellular trafficking of nanoparticles 
Raw 264.7 (1  105 cells) were allowed to attach to a 
sterile microscopic coverslip at 37 °C for 24 h followed 
by incubation with 5 μg·mL−1 OVAF-loaded nano-
particles (IMHCSs and CNTs) and OVAF + QuilA  
for 8 h. The lysosomes were further stained with 
LysoTracker Red DND-99 (Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
instructions. 
2.12 Effect of IMHCS-OVA on dendritic cell and 
macrophage maturation 
Briefly, mice spleens were passed through a cell strainer 
to obtain a single-cell suspension and red blood cells 
were lysed using erythrocyte lysis buffer (Sigma– 
Aldrich). The resulting cells were seeded in a 96-well 
plate at a density of 2 × 105 cells/well in phenol-free 
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Iscove’s Modified Dulbecco’s Media (IMDM, Glutamax 
medium, Gibco ®, Life Technologies) supplemented 
with 10% FBS, 50 μM 2-mercaptoethanol (Gibco®, 
Life Technologies), penicillin (1%), and streptomycin 
(1%) (Gibco®, Life Technologies). OVA, OVA + QuilA, 
OVA + CNT, and OVA + IMHCS were added to the 
wells and incubated for 24 h. Adherent cells were 
scraped from the plate and incubated with Fc-block 
(BD Biosciences) for 20 min at 4 °C, centrifuged, and 
resuspended in buffer containing CD11c (eBioscience, 
San Diego, CA, USA), F4/80, CD40, CD80, and CD86 
major histocompatibility class II (MHCII, BioLegend, 
San Diego, CA, USA) antibodies for 30 min at 4 °C. 
The cells were then centrifuged and resuspended in 
0.5 mL FACS buffer (PBS, 0.02% sodium azide, 0.5% 
BSA) and analyzed with an LSR II flow cytometer (BD 
Biosciences). The fluorescence intensities of dendritic 
cells and macrophages treated with PBS were measured 
as negative controls. The cell population costimulatory 
for dendritic cells (CD11c)/macrophages (F4/80) and 
other fluorochrome markers (CD40, CD80, CD86, 
MHCII) were analyzed as percent (%) positive cells using 
flow cytometry (FACS Aria III, BD Biosciences) and 
the data were processed using the FlowJo software. 
2.13 Animals 
Naïve 8-week-old C57BL/6J female mice were purchased 
from the Biological Resource Facility (Brisbane, 
Australia). Animal studies were conducted using    
5 groups with 5 mice/group. The mice were caged in 
high-efficiency particulate air-filtered polycarbonate 
cages and were given ad libitum access to food and 
water. All mice were housed in a pathogen-free 
environment at controlled temperature (21 ± 1 °C) and 
a 12-h/24-h light cycle was maintained. All experiments 
involving animals were approved by the Animal Ethics 
Committee, The University of Queensland (AIBN/ 
464/14/ARC). Experiments were blinded to treatment 
groups. Animals were closely monitored twice daily 
and remained in good health for the duration of the 
study with no visible deleterious health effects.  
2.14 Immunizations 
At the onset of the experiment, mice were divided 
into 5 treatment groups (n = 5). Group 1 and 2 mice 
were injected with OVA (50 μg) plus QuilA (25 μg) 
and OVA (50 μg) as two positive control groups. Group 
3 mice were injected with OVA-loaded IMHCS pellets 
(prepared as described above) equivalent to 50 μg 
OVA suspended in sterile saline solution. Group 4 mice 
were injected with IMHCS (100 μg) as a negative 
control group. Group 5 was again a negative control 
including unimmunized mice. Dose volumes of  
100 μL (in 0.9% saline, Pfizer, New York, NY, USA) 
were administered by subcutaneous injection at the 
tail base using a sterile 27-gauge needle (BD Biosciences). 
Three injections were administered at 3-week intervals 
to all treatment groups. Blood was obtained from each 
mouse through retro-orbital bleeds using heparin 
coated hematocrit tubes (Hirschmann Laborgeräte, 
Heilbronn, Germany) before each immunization. 
Fourteen days after the third immunization, the 
animals were sacrificed and blood was collected and 
analyzed for antibody titers, whereas splenocytes were 
collected and analyzed for cytokine (IFN-γ and IL-4) 
concentrations. 
2.15 Estimation of OVA antibody response 
The OVA-specific IgG response was determined by 
enzyme-linked immunosorbent assay (ELISA) as 
previously described [16, 32]. Briefly, microtiter plates 
(96-well, Nunc, Maxisorb, Roskilde, Denmark) were 
coated with OVA antigen in PBS solution (10 μg·mL–1, 
50 μL) for 24 h at 25 °C. The coating solution was then 
removed and the plates were washed once with 200 μL 
PBS-T (1 PBS containing 0.1% Tween 20). Coated 
plates were blocked with BSA (5%) and skimmed milk 
powder (5%, Fonterra, Auckland, New Zealand) for 
1 h at room temperature (RT). The plates were then 
washed three times with 200 μL PBS-T, after which 
mouse sera diluted with PBS was added in the range 
of 1:1.5 × 104–1:3 × 107. Unreacted antibodies from 
mouse sera were removed by washing with 200 μL 
PBS-T. The plates were further incubated with 100 μL 
secondary antibody, horseradish peroxidase (HRP)- 
linked rabbit anti-mouse IgG (Sigma-Aldrich) (1:5,000 
in PBS), or HRP-linked goat anti-mouse IgG1 (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) (1:2,000 
in PBS) or HRP-linked goat anti-mouse IgG2A (Santa 
Cruz Biotechnology, Inc.) (1:2,000 in PBS) for 1 h at RT. 
The substrate solution 3,3’,5,5’-tetramethylbenzidine  
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(100 μL, Life Technologies) was used for color develop-
ment. Color development was stopped using 1 N HCl 
and the optical density was read at 450 nm using a 
Tecan Infinite M 200 Pro Plate reader (Männedorf, 
Switzerland). Titers were determined as the reciprocal 
of the sample dilution corresponding to three standard 
deviations above the mean OD value of the population 
of negative sera. 
2.16 Isolation of murine splenocytes and enzyme- 
linked spot (ELISPOT) assay 
Spleens were removed aseptically from the mice 
and placed in 5 mL of ice-cold DMEM supple-
mented with 10% fetal bovine serum, 20 mM 4-(2- 
hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2- 
hydroxyethyl)piperazine-N-(2-ethanesulfonic acid  
(HEPES buffer, pH 7.3, Sigma-Aldrich), 1 M sodium 
pyruvate, 1 M Glutamax, 100 U·mL−1 penicillin G, 100 
mg·mL−1 streptomycin, and 0.25 mg·mL−1 Fungizone. 
The spleens were disrupted using a plunger connected 
to a 3-mL syringe and passed through 100-μm mesh. 
The resulting cells were washed three times with    
5 mL DMEM and centrifuged at 2,500 rpm for 5 min at 
4 °C and then resuspended in 1 mL lysis buffer (0.15 M 
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA) for 5 min at 
RT. The washing steps were repeated three times with 
DMEM (5 mL) each. Cell pellets were resuspended in 
2 mL DMEM and the cell numbers were determined by 
staining with 0.2% trypan blue. Cells from each mouse 
spleen were seeded in triplicate onto polyvinylidene 
fluoride ELISPOT plates precoated with monoclonal 
IFN-γ (Mabtech, Cincinnati, OH, USA) capture antibody 
or monoclonal IL-4 capture antibody (Mabtech). Next, 
2.5 × 105 cells were incubated in complete DMEM at 
37 °C and 5% CO2 for 40 h in the presence or absence 
of 1 mg·mL–1 OVA antigen or polyclonal activator 
concavalin A as a positive control. IFN-γ and IL-4 
ELISPOT assays were performed according to the 
manufacturer’s instructions. The ELISPOT plates were 
read on an ELISPOT reader (AID ELISPOT reader, 
Strassberg, Germany). 
2.17 IFN-γ secretion level in RAW 264.7 cells 
RAW 264.7 cells were seeded into a 96-well plate at  
a density of 2  105 cells/well in complete DMEM 
supplemented with 10% FBS and 1% Penicillin and 
Streptomycin (PS). After incubation for 24 h, the cells 
were treated with OVA (10 μg)-loaded IMHCS (10 μg) 
and physically mixed with IMHCS (10 μg) and OVA 
(10 μg) or PBS (a negative control) for 48 h. Cytokine 
IFN-γ levels in the cells were measured using an 
ELISA kit according to the manufacturer’s protocol. 
2.18 Statistical analysis 
Data are reported as the mean ± S.E.M and differences 
between groups were analyzed by two-way ANOVA 
followed by Tukey’s post-test (GraphPad Software, 
La Jolla, CA, USA).  
3 Results and discussion 
IMHCSs were prepared using a sequential hetero-
geneous nucleation process as reported in our previous 
work [31]. SEM images (Fig. 2(a)) showed that IMHCSs 
had a uniform and invaginated spheroidal morphology. 
TEM images (Fig. 2(b)) depicts a bilayered and hollow 
internal structure of IMHCSs with a uniform outer 
diameter of 192.3  11.3 nm. The porous nature on the 
wall can be directly observed in both the SEM and 
TEM images. 
Nitrogen sorption results of IMHCSs indicated a 
type IV adsorption isotherm (Fig. 2(c)). The Barrett– 
Joyner–Halanda pore size distribution curve derived  
 
Figure 2 (a) SEM and (b) TEM images of IMHCS, (c) N2 
adsorption–desorption isotherm of IMHCS, (d) particle size 
distribution curves of IMHCS in ethanol, PBS, and DMEM by 
DLS measurement. 
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from the adsorption branch displays one peak centered 
at 15.3 nm (Fig. S1 in the Electronic Supplementary 
Material (ESM)), corresponding to the interlayer distance 
between the inner and outer layers. The pore diameter 
of 7.3 nm calculated from the desorption branch 
indicated a relatively large entrance size in the carbon 
shell. The BET surface area and pore volume of IMHCSs 
were 1,085 m2·g–1 and 2.85 cm3·g–1, respectively. To 
demonstrate the advantages of IMHCSs in vitro, 
commercially available CNTs (Fig. S2 in the ESM) 
with a pore size of approximately 2 nm, BET surface 
area of 138 m2·g−1, and pore volume of 0.93 cm3·g−1 
(Fig. S3 in the ESM) were used. 
The particle size and polydispersity of IMHCSs 
were further investigated in ethanol and biological 
media by DLS measurement. As shown in Fig. 2(d), 
the average particle size of IMHCSs in ethanol    
was 195 nm. The narrow size distribution and low 
polydispersity index (0.1) indicated that the particles 
were of uniform particle size and showed excellent 
dispersibility in ethanol. The hydrated diameter of 
IMHCSs in PBS was approximately 230 nm, which is 
larger than that in ethanol because of the surrounding 
water molecules [31]. The size distribution curve in 
DMEM containing 10% FBS showed two peaks at 
approximately 7.5 and 225 nm, attributed to FBS and 
IMHCS, respectively. The polydispersity index value 
in DMEM was relatively large (0.56) because two 
populations of sizes were present. Optical images of 
the CNT and IMHCS (Fig. S4 in the ESM) indicated 
that the IMHCS has better dispersibility as compared 
to the CNT. Numerous reports have demonstrated 
stronger adjuvant effectiveness of nanoparticles over 
those with micrometer-size in immune response 
amplification [13]. IMHCSs with smaller particle sizes 
and better dispersity may be a more potent adjuvant 
than CNTs. 
In this study, OVA (45 kDa, 7 nm × 4 nm × 4 nm) was 
used as the model antigen to evaluate the adjuvant 
effect of IMHCSs. The loading kinetics of OVA on 
IMHCSs and CNTs were studied in PBS. As shown in 
Fig. 3(a), IMHCSs reached a high loading capacity of    
1,040 μg·mg−1 within 10 h. In contrast, OVA adsorption 
reached equilibrium at 3 h for CNTs (Fig. 3(a)) with  
a maximum loading of 225 μg·mg−1, indicating that 
OVA was loaded mainly on the outer surface of the 
CNT. Compared to previously reported mesoporous 
carbon nanoparticles with a small mesopore size   
(5 nm) and low antigen loading (79 ± 4.16 μg·mg−1) [18], 
IMHCSs showed a 13-fold higher antigen-loading 
capacity. IMHCSs showed higher loading capacity  
of OVA than CNTs, silica nanoparticles [16], PLGA 
nanoparticles [15], and layered double hydroxide 
nanoparticles [17], which is attributed to the inherent 
hydrophobic nature of pristine carbon and unique 
nanostructure with a large and accessible surface area 
and pore volume of IMHCSs. 
The sustained release of antigen from adjuvants is 
considered one of the main reasons for adjuvants’ 
ability to promote an immune response [34]. It was 
reported that porous inorganic particles with pore 
sizes larger than antigens were beneficial for sustained 
antigen release and elicited stronger immune responses 
by successfully encapsulating the antigen proteins 
inside the pores [35]. The release behavior of OVA- 
loaded nanocarriers in PBS was investigated. IMHCSs 
displayed (Fig. 3(b)) a two-step [36] OVA release 
pattern with a fast release step of 50% in the first 6 h, 
followed by a sustained release step of 78% until 24 h. 
The fast release of OVA may be attributed to the OVA 
loaded on the outer surface of the IMHCS, and    
the sustained release to antigens loaded inside the 
interspace of two layers of the IMHCS. In comparison, 
CNTs showed a burst release of 100% within 2 h  
(Fig. 3(b)). This release pattern of OVA from pristine  
 
Figure 3 (a) Adsorption kinetics of OVA in PBS on IMHCS and 
CNT, (b) cumulative release of OVA in PBS from IMHCS and 
CNT, cell viability of (c) bare IMHCS and CNT and (d) OVA + 
QuilA and OVA + IMHCS. 
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CNTs further indicates that OVA was loaded only on 
the outer surface of the CNT with a small pore size of 
2 nm. Unlike pristine IMHCSs for which controlled 
release can be achieved by adjusting the nanostructure 
and nanopores, CNTs without chemical functio-
nalization are not suitable as nano-carriers for high 
loading and sustained release of OVA. 
The cytotoxicity of OVA plus QuilA, OVA-loaded 
IMHCS, blank IMHCS, and blank CNT was tested  
on normal HEK 293 cells before administration to 
animals. The in vitro cell toxicity studies (Fig. 3(c)) 
confirmed that the blank IMHCSs showed good 
biocompatibility with no obvious cell toxicity over a 
wide concentration range (12.5–100 μg·mL−1), indicating 
excellent biosafety. The blank CNT group showed high 
toxicity even at low concentration of 12.5 μg·mL−1 
(Fig. 3(c)). This observation is in agreement with 
literature reports suggesting that pristine CNT is toxic 
because of impurities or intrinsic structural defects 
[37]. At the same doses used in animal studies,  
OVA (50 μg·mL−1) plus QuilA (25 μg·mL−1) and OVA 
(50 μg·mL−1)-loaded IMHCS (50 μg·mL−1) exhibited 8% 
and 64% cell viability respectively, suggesting that 
the OVA-loaded IMHCS vaccine formulation is safer 
than OVA plus QuilA (Fig. 3(d)). This observation   
is in accordance with literature reports stating that 
QuilA induces local reactions, hemolytic effects, and 
systemic toxicity [38], while carbon nanoparticles have 
excellent biocompatibility [39, 40].  
The antigens should be taken up, processed, and 
presented on APCs in order to generate an efficient 
immune response after immunization [41, 42]. Uptake 
of bare nanoparticles tagged with FITC was studied 
in RAW 264.7 cells using confocal microscopy. The 
feeding amount of FITC was kept constant in all 
groups. As shown in the confocal microscopy images 
(Fig. S5 in the ESM), the control without treatment 
showed no fluorescence. Cells with CNTs tagged 
with FITC (CNT-F) showed slightly higher fluorescence 
intensity compared to the control group. However, 
mono-dispersed IMHCSs tagged with FITC (IMHCS-F) 
showed the highest fluorescence intensity, indicating 
highly improved uptake performance compared to 
CNTs.  
To further investigate the delivery performance of 
OVA conjugated with FITC (OVAF) using nanoparticles 
and QuilA in RAW 264.7 cells, OVAF was adsorbed 
onto the nanoparticles (CNT and IMHCS) and QuilA 
and uptake performance was estimated by confocal 
microscopy and FACS. The mass ratio of particles/ 
QuilA to OVAF was the same in all groups. According 
to the FACS results shown in Fig. 4, IMHCSs are  
the most effective nanocarriers for delivering OVAF 
into RAW cells among all the groups based on mean 
fluorescence intensity and the percentage of positive 
cells. From the confocal images shown in Fig. S6 in the 
ESM, IMHCS also showed the highest fluorescence 
intensity compared to the QuilA and CNT groups, 
consistent with the FACS results. Thus, IMHCS with 
an intact carbon composition, monodispersed nanosize, 
and large porosity have high cellular uptake and 
OVA delivery efficacy [24]. 
The intracellular fate of the delivered protein 
determines the type of MHC class stimulated by the 
antigen. If proteins are degraded by proteasomes, 
MHC I protein markers will be enhanced, causing   
a cell-mediated response [43, 44]. If the proteins are 
entrapped in endosomes, they are degraded in endo/ 
lysosomes and presented on the cell surface as MHC 
II antigens, which eventually helps in enhancing  
the antibody-mediated immune response [43, 44]. To 
study the intracellular fate of OVA, lysosomes were 
stained using Lysotracker (red) and nuclei were stained 
with DAPI (blue). As indicated in the confocal images 
(Fig. 5), OVAF plus QuilA or CNT showed small 
increases in green fluorescence (from OVAF) located 
in the lysosomes compared to in the control. OVAF plus 
IMHCS showed considerably higher green fluorescence 
intensity in lysosomes compared to in other groups 
(control, OVAF, OVAF + CNT, OVAF + QuilA). Moreover,  
 
Figure 4 Uptake of OVAF-loaded nanoparticles in RAW 264.7 
cells. 
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Figure 5 RAW 264.7 cells were incubated with OVA-FITC- 
loaded nanoparticles for 8 h followed by fluorescent staining of 
lysosomes using LysoTracker red DND 99 to identify lysosomes 
(red), nucleus (blue), and OVAF (green). 
both green and red fluorescence overlapped to give a 
yellow color in the merged images for OVAF + IMHCS, 
indicating that the OVAF did not undergo detectable 
endo-lysosomal escape. These results indicate that 
OVA was located in endo-lysosomes, which can cause 
activation of MHC ΙΙ marker enhancement and induce 
a higher antibody response [45].  
Matured dendritic cells are the most efficient 
immunological cells. The maturation of the dendritic 
cells is characterized by upregulation of surface 
costimulatory molecules (CD80, CD86, CD40) and 
various cell surface markers such as MHC II [46, 47]. In 
this study, the antigens were localized in endosomes; 
thus, we further tested the activation of MHC II 
molecules on APCs by conducting a splenocyte 
maturation test. Splenocytes were isolated from the 
mouse spleens and studied for maturation after 
stimulation with OVA, OVA + QuilA, and OVA + 
IMHCS using FACS ex vivo. Because CNT was highly 
aggregated and showed low OVA loading, high 
toxicity, and reduced uptake in the APCs, CNT was 
excluded from the following studies. 
As shown in the maturation data obtained from 
FACS in Fig. 6, the negative control showed no 
noticeable maturation for MHC II/CD40/CD 80/CD86 
in dendritic cells (CD11c-positive) and macrophages 
(F4/80-positive). In both dendritic cells and macrophages, 
the cells treated with OVA + IMHCS showed higher 
expression of MHC II molecules compared to the 
OVA alone and OVA + QuilA groups. Moreover, CD40 
was significantly upregulated. However, there was no 
significant difference in CD80 and CD86 expression on 
dendritic cells and macrophages treated with OVA + 
IMHCS, OVA, and OVA + QuilA. 
To study the OVA-specific immune response  
and adjuvant effect of IMHCS compared with QuilA, 
C57BL/6J female mice were injected with OVA-loaded 
IMHCS, pristine OVA, OVA + QuilA, and blank 
IMHCS. All formulations were prepared on the day 
of immunization and 3 injections at 3-week intervals 
were administered. Pre-immune sera and sera at 2 
weeks after each injection were collected. All animals 
remained in healthy conditions throughout the study. 
Sera collected 14 days after the second boost injection 
were analyzed for an OVA-specific IgG response by 
ELISA. 
The endpoint titers for the above five groups 
(including the unimmunized control group) are 
summarized in Fig. 7(a). The two negative control 
groups (blank IMHCS and the unimmunized group) 
showed a negligible immune response compared to 
the two positive groups (OVA + IMHCS and OVA + 
QuilA). The pristine OVA group showed a higher res-
ponse than the two negative groups, but significantly  
 
Figure 6 Splenocyte maturation in (a) CD11c-positive dendritic 
cells and (b) F4/80-positive macrophages. Flow cytometer com-
parison of maturation markers (CD40, CD80, MHCII, and CD86). 
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Figure 7 (a) IgG endpoint titer data for 5 groups, (b) OVA- 
specific IgG antibody isotypes (IgG1 and IgG2a) levels, (c) IFN-γ 
and (d) IL-4 secretion by splenocytes. Data are expressed as the 
mean ± S.E.M. (n = 5), *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001 two way ANOVA test followed by Tukey post-test. 
lesser than the two positive groups, suggesting that an 
adjuvant is required to induce an appreciable immune 
response. The endpoint titer induced by OVA + 
IMHCS (6.24  106  0.78  106) was higher than in 
the OVA + QuilA group (2.60  106  0.98  106). This 
increase may be attributed to the intrinsic hydro-
phobicity of IMHCS [48], higher antigen uptake, and 
enhanced maturation of APCs. 
Next, to study the nature of the adaptive immune 
response evoked by the IMHCS, IgG isotypes IgG1 
and IgG2a indicative of a Th2- or Th1-biased response 
were measured in the serum obtained 14 days after 
the second boost injection of protein [15]. As shown 
in Fig. 7(b), the ratio of IgG1/IgG2a was close to 1 for 
the OVA + QuilA group. For the OVA + IMHCS group, 
the IgG1 concentration was significantly higher (p < 
0.0001), while IgG2a was similar compared to the OVA + 
QuilA group, leading to a higher IgG1/IgG2a ratio 
(2.00 ± 0.12) and suggesting a Th2-polarized immune 
response [49]. The increased expression of IgG1 is 
consistent with the higher activation of CD40 observed 
in ex vivo studies [50]. The other groups showed lower 
IgG levels, and thus their isotype concentrations were 
not analyzed. 
Cytokines such as IFN-γ and IL-4 are considered  
to be important mediators in the initiation of cell- 
mediated and humoral immune responses, respectively 
[51], and thus IFN-γ and IL-4 levels were further 
analyzed by the ELISPOT technique. As shown in 
Fig. 7(c), the concentration of IFN-γ secreted in the 
OVA + QuilA group was 1,954  435 spots·million−1 
whereas the OVA + IMHCS group showed a lower 
IFN-γ concentration of 1,108  594 spots·million−1. Mice 
administered with pristine OVA showed an even lower 
IFN-γ concentration of 252  141 spots·million−1. The 
IFN-γ concentration further decreased to 144  91 
and 122  53 spots·million−1 in the blank IMHCS and 
unimmunized groups, respectively. For IL-4 expression 
(Fig. 7(d)), OVA + IMHCS induced 4-fold higher IL-4 
(122  58 spots·million−1) than OVA + QuilA (450  110 
spots·million−1), whereas pristine OVA, blank IMHCS, 
and unimmunized mice showed no significant IL-4 
response. 
Previous studies suggested that IL-4 expression level 
is an indicator of the Th2 response [52]. The higher 
IL-4 response observed in the OVA + IMHCS group 
compared to the OVA + QuilA group is consistent with 
the higher IgG1/IgG2a ratio observed in Fig. 7 and 
higher MHCII expression in the maturation study 
(Fig. 6), all indicating a Th2-polarized immune response 
[52]. The high secretion of IL-4 may stimulate B cells 
to secrete high concentrations of antibodies. This 
suggests that the Th2-polarized immune response 
occurs because of the hydrophobic nature of IMHCSs. 
The intrinsic hydrophobicity of IMHCSs facilitates 
their accommodation of antigen proteins via the 
interaction between IMHCSs and hydrophobic regions 
of proteins. Hydrophobic interactions between IMHCSs 
and cell membranes also promote high uptake in 
endo/lysosomes but without effective escape, leading 
to activation of costimulatory molecules such as MHCII 
and CD40 and a subsequent Th2-biased immune 
response.  
Other inorganic carriers, typically metal oxides, 
have been reported as excellent adjuvants for Th2- 
biased immune responses with strong IgG1 level, 
including aluminum oxyhydroxide [53] and aluminum 
silicates [54]. The generation of reactive oxygen species 
induced by these metal oxides may be responsible for 
the Th2 immune response [55], which differs from 
IMHCS. Compared to Quil A, the Th1 immune res-
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ponse induced by IMHCSs was lower based on the 
lower IFN-γ level. However, compared to the OVA 
group, there was a higher level of IFN-γ, which  
may maintain the T cell response and sustain the Th1 
response [56]. 
To understand the roles of IMHCSs in the 
significantly improved IgG and cytokine levels, we 
conducted in vitro analysis of IFN-γ cytokine secretion 
in RAW 264.7 cells after treatment with OVA-loaded 
IMHCS (OVA + IMHCS) and physically mixed OVA + 
IMHCS. As shown in Fig. S7 in the ESM, the cells 
treated with physically mixed OVA + IMHCS showed 
a significantly lower IFN-γ secretion level (460 pg·mL−1) 
than that with OVA + IMHCS (2188 pg·mL−1). However, 
this level was still much higher than in the negative 
control group (PBS). These results indicate that both 
the adjuvant effect and delivery function of IMHCS 
(sustained release and enhanced uptake) contribute 
to potent immune responses with improved IgG and 
cytokine levels in mice, similar to a PLGA nanoparticle 
system [15]. 
QuilA is more toxic than IMHCS, which may be 
related to the immune effect of adjuvants. It has been 
reported that necrotic cells secrete various damage- 
associated molecular patterns during the necrosis 
process, which activate a cascade of immune reactions 
and consequently drive a Th1 immune response [57, 58]. 
Thus, the toxicity of QuilA may play a role in Th1 
responses. Although IMHCS has a low cellular toxicity 
and high Th2-biased immune response, their capability 
in inducing cell-mediated immunity should be 
improved. Future studies should be devoted to the 
development of adjuvants with low toxicity and both 
high Th1 and Th2 immune responses. 
4 Conclusions 
In conclusion, we explored the adjuvant effect of 
pristine IMHCSs using OVA protein as a model antigen. 
IMHCSs exhibited significantly higher loading capacity, 
more sustained release of OVA, and an improved 
safety profile compared to most of the studied CNTs. 
IMHCSs also showed advantages in intracellular 
delivery of OVA in APCs and splenocyte maturation 
compared with Quil A. OVA delivered by IMHCSs 
localized in endosomal/lysosomal compartments in 
APCs, which may account for the enhanced MHC II 
activation compared to Quil A. In vivo studies revealed 
that OVA-loaded IMHCSs induced much stronger 
total IgG responses compared to OVA + QuilA. Higher 
IgG1 levels than IgG2a suggested a Th2-polarized 
immune response by IMHCS + OVA, which may be 
explained by the enhanced endo/lysosome delivery 
of OVA by IMHCSs. Thus, IMHCSs with a strong 
antibody response may have potential as an adjuvant 
for vaccines against infectious bacterial diseases. 
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